Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial

BACKGROUND: Pembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC). However, the cost-effectiveness of pembrolizumab versus chemotherapy in China remains uncertain. OBJECTIVE: This analysis aimed to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Wenxiu, Ding, Haiying, Fang, Qilu, Zheng, Xiaowei, Tong, Yinghui, Xu, Gaoqi, Yang, Guonong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751211/
https://www.ncbi.nlm.nih.gov/pubmed/33371020
http://dx.doi.org/10.1136/bmjopen-2020-038867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751211/
https://www.ncbi.nlm.nih.gov/pubmed/33371020
http://dx.doi.org/10.1136/bmjopen-2020-038867

Ejemplares similares